Waters Corporation WAT SPXR3KPHARMA

Healthcare · Diagnostics & Research · United States

https://www.waters.com

Company Profile ↓

$409.38

+37.92% 1Y

Mkt Cap$40.20B

P/E101.58

P/B2.61

52W High$421.26

52W Low$283.32

Book Value$155.78

EPS (TTM)$4.03

Company Overview

Waters Corporation provides analytical workflow solutions in Asia, the Americas, and Europe. The company operates through two segments, Waters and TA. The company designs, manufactures, sells, and services liquid chromatography, as well as mass spectrometry (MS) technology systems and supports products, including chromatography columns, and other consumable products. It also designs, manufactures, sells, and services thermal analysis, rheometry, and calorimetry instruments for use in predicting the suitability and stability of fine chemicals, pharmaceuticals, water, polymers, metals, and viscous liquids for various industrial, consumer goods, and healthcare products, as well as for life science research; and develops and supplies software-based products that interface with its instruments, as well as other manufacturers' instruments. In addition, the company offers MS technology, which is used in drug discovery and development comprising clinical trial testing, the analysis of proteins in disease processes, nutritional safety analysis, and environmental testing. Its products are used by clinical, pharmaceutical, biochemical, industrial, nutritional safety, environmental, academic, and governmental customers working in research and development, quality assurance, and other laboratory applications. The company was founded in 1958 and is headquartered in Milford, Massachusetts.

Why Investors Should Care

Healthy Capital Returns

Return on capital employed stands at 20.9%.

Conservative Balance Sheet

Carries low leverage with a debt-to-equity ratio of 0.33.

Positive Free Cash Flow

Generates positive free cash flow, funding growth and shareholder returns internally.

Recent Developments

Dec 2025 Revenue of $3.17B (+7.0% YoY); net profit $642.63M.
Trailing 12 Months Year-on-year growth — revenue +113.3%, earnings +0.8%.
5-Year Trend Long-term compounding — revenue CAGR 4.6%, profit CAGR 2.8%.

Growth & Price Performance

Compounded Sales Growth

5 Years:	4.60%
1 Year:	113.30%

Compounded Profit Growth

5 Years:	2.80%
1 Year:	0.75%

Stock Price Performance

1 Year:	+37.92%
6 Months:	+35.31%
3 Months:	+12.05%
1 Month:	+2.42%

Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.

Technical Snapshot Bullish

52-Week Range 91% of range

$283.32 $421.26

Trend Signals

Price vs 50-DMAAbove
Price vs 200-DMAAbove
RSI (14)53.59 · Neutral

Price Performance

1M+2.42%

3M+12.05%

6M+35.31%

1Y+37.92%

Valuation vs Sector

P/E of 101.58 is above the sector median of 25.17 — pricier than peers.

Auto-generated from price history and fundamentals; not investment advice.

Price Chart

Robinhood TradingView

Fundamental Growth Charts

Period: Metric:

Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.

PROS

Healthy ROCE of 20.9%.
Generates positive free cash flow.
In a confirmed uptrend (50-DMA above 200-DMA).

CONS

Trading at a high P/E of 101.6.

* The pros and cons are auto-generated from financial metrics.

Valuation

Stock P/E

101.58

Industry PE

25.17

Forward P/E

24.71

PEG Ratio

1.74

Book Value

$155.78

Price to Book

2.61

P/S

8.60

EV/EBITDA

30.80

Dividend Yield

0.00%

Growth (CAGR)

Revenue 5Y

4.60%

Profit 5Y

2.80%

Revenue (YoY)

113.30%

Earnings (YoY)

0.75%

Profitability & Returns

ROCE

20.92%

ROE

1.92%

ROA

3.53%

Profit Margin

3.59%

Op Margin

10.03%

Gross Margin

56.34%

EPS (Latest Qtr)

$-0.87

EPS (TTM)

$4.03

Balance Sheet & Liquidity

Debt/Equity

0.33

Quick Ratio

1.27

Current Ratio

1.73

Debt

$5.09B

Total Assets

$24.53B

Current Assets

$4.06B

Working Capital

$908.15M

Ownership

Promoter Holding

0.10%

Chg in Prom Hold

FII / Inst Holding

102.30%

Chg in FII Hold

0.02%

Financial Snapshot

Enterprise Value

$40.20B

Total Revenue (TTM)

$4.64B

EBITDA

$1.45B

Free Cash Flow

$539.81M

Operating Cash Flow

$549.56M

Shares Outstanding

98.19M

Gross Margin

56.34%

Payout Ratio

0.00%

Peer comparison

Peer companies in the same sector (Healthcare).

#	Name	CMP $	P/E	Mkt Cap	Div Yld %	ROCE %	ROE %	Rev CAGR 5Y %	Profit CAGR 5Y %
1	WAT Waters Corporation SPXR3KPHARMA	409.38	101.58	$40.20B	0.00%	20.92%	1.92%	4.60%	2.80%
2	LLY Eli Lilly and Company SPXR3KPHARMA	1,149.36	38.57	$1.02T	0.58%	-	102.29%	7.20%	11.41%
3	JNJ Johnson & Johnson SPXR3KPHARMA	275.23	31.97	$663.28B	2.09%	14.88%	25.74%	2.43%	4.76%
4	ABBV AbbVie Inc. SPXR3KPHARMA	256.46	72.45	$453.19B	2.84%	10.47%	-129.24%	1.75%	-29.06%
5	MRK Merck & Co., Inc. SPXR3KPHARMA	150.33	120.26	$371.29B	2.65%	-	34.70%	5.64%	10.01%
6	UNH UnitedHealth Group Incorporated SPXR3KPHARMA	397.14	25.54	$356.47B	2.33%	9.74%	14.15%	10.40%	5.43%
7	NVS Novartis AG PHARMA	159.99	24.20	$304.10B	3.03%	21.09%	30.35%	9.25%	26.22%
8	AZN AstraZeneca PLC NDXPHARMA	162.70	24.36	$252.33B	1.98%	15.97%	21.96%	9.82%	45.96%
9	AMGN Amgen Inc. NDXSPXR3KPHARMA	437.23	27.14	$235.98B	2.49%	13.95%	91.47%	5.51%	5.55%

Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios

Quarterly Results

Figures in USD.

Metric	Sep 2018	Dec 2018	Mar 2019	Jun 2019	Sep 2019	Dec 2019	Mar 2020	Jun 2020	Sep 2020	Dec 2020	Mar 2021	Apr 2021	Jun 2021	Jul 2021	Sep 2021	Oct 2021	Dec 2021	Mar 2022	Apr 2022	Jun 2022	Jul 2022	Sep 2022	Oct 2022	Dec 2022	Mar 2023	Apr 2023	Jun 2023	Jul 2023	Sep 2023	Dec 2023	Mar 2024	Jun 2024	Sep 2024	Dec 2024	Mar 2025	Jun 2025	Sep 2025	Dec 2025	Mar 2026	Apr 2026
Revenue	578.02M	715.02M	513.86M	599.16M	577.28M	716.29M	464.94M	519.98M	593.78M	786.66M	608.54M	608.54M	681.65M	681.65M	659.23M	659.23M	836.45M	690.57M	690.57M	714.32M	714.32M	708.55M	708.55M	858.51M	684.67M	684.67M	740.58M	740.58M	711.69M	819.47M	636.84M	708.53M	740.30M	-	662.00M	771.33M	799.89M	932.36M	1.27B	1.27B
Cost of Revenue	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	277.00M	321.41M	327.81M	362.86M	679.00M	-
Gross Profit	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	385.00M	449.93M	472.08M	569.50M	588.00M	-
Operating Expenses	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	233.00M	261.71M	279.97M	298.98M	635.00M	-
Operating Income	171.67M	244.53M	121.15M	177.65M	173.24M	236.42M	68.28M	155.11M	158.38M	263.71M	171.27M	171.27M	196.42M	196.42M	191.81M	191.81M	262.20M	195.47M	195.47M	199.63M	199.63M	192.01M	192.01M	286.28M	174.17M	174.17M	199.86M	199.86M	179.43M	264.22M	133.85M	189.11M	211.13M	-	152.00M	188.21M	192.11M	270.52M	-47.00M	-47.00M
EBITDA	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	207.00M	243.06M	249.43M	331.01M	167.00M	-
Interest Expense	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	14.00M	14.35M	26.64M	14.29M	48.00M	-
Pretax Income	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	143.00M	177.69M	170.12M	264.18M	-88.00M	-
Tax Provision	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	22.00M	30.58M	21.20M	38.97M	-16.00M	-
Net Income	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	102.20M	142.74M	161.50M	-	121.00M	147.11M	148.92M	225.21M	-72.00M	-72.00M
Diluted EPS	1.83	2.46	1.51	2.08	2.07	3.12	0.86	1.98	2.03	3.49	2.37	2.37	2.69	2.69	2.60	2.60	3.52	2.62	2.62	2.72	2.72	2.60	2.60	3.81	2.38	2.38	2.55	2.55	2.27	3.65	1.72	2.40	2.71	-	2.03	2.47	2.50	3.77	-0.87	-0.87
R&D Expense	35.17M	38.11M	35.06M	36.49M	34.33M	37.07M	34.99M	31.16M	34.97M	39.66M	38.09M	38.09M	44.95M	44.95M	41.99M	41.99M	43.33M	40.47M	40.47M	44.01M	44.01M	43.44M	43.44M	48.28M	42.69M	42.69M	45.87M	45.87M	41.99M	44.39M	44.59M	46.18M	45.34M	46.91M	47.00M	48.55M	53.64M	46.90M	-	96.00M

Profit & Loss (Annual)

Figures in USD.

Metric	Dec 2007	Dec 2008	Dec 2009	Dec 2010	Dec 2011	Dec 2012	Dec 2013	Dec 2014	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024	Dec 2025
Revenue	1.47B	1.58B	1.50B	1.64B	1.85B	1.84B	1.90B	1.99B	2.04B	2.17B	2.31B	2.42B	2.41B	2.37B	-	2.97B	2.96B	2.96B	3.17B
Cost of Revenue	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	1.25B	1.20B	1.20B	1.29B
Gross Profit	841.93M	913.86M	903.82M	990.07M	1.12B	1.11B	1.12B	1.16B	1.20B	-	-	-	-	-	-	1.72B	1.76B	1.76B	1.88B
Operating Expenses	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	840.58M	943.52M	920.26M	1.07B
Operating Income	348.88M	389.75M	394.60M	449.93M	528.60M	511.49M	517.34M	517.91M	567.45M	625.04M	662.20M	739.77M	708.46M	645.49M	-	883.19M	817.68M	837.92M	802.59M
EBITDA	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	1.02B	1.00B	1.04B	1.03B
Interest Expense	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	48.80M	98.86M	89.68M	69.55M
Pretax Income	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	837.85M	736.24M	754.87M	754.88M
Tax Provision	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	130.09M	94.01M	117.03M	112.25M
Net Income	-	-	-	-	-	461.44M	450.00M	431.62M	469.05M	521.50M	20.31M	593.79M	592.20M	521.57M	-	707.75M	642.23M	637.83M	642.63M
Diluted EPS	2.62	3.21	3.34	-	-	-	5.20	5.07	5.65	6.41	0.25	7.65	8.69	8.36	-	11.73	10.84	10.71	10.76
R&D Expense	80.65M	81.59M	77.15M	84.27M	92.35M	96.00M	100.54M	107.73M	118.55M	125.19M	132.59M	143.40M	142.96M	140.78M	168.36M	176.19M	174.94M	183.03M	195.71M

Balance Sheet (Annual)

Figures in USD.

Metric	Dec 2006	Dec 2007	Dec 2008	Dec 2009	Dec 2010	Dec 2011	Dec 2012	Dec 2013	Dec 2014	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024	Dec 2025
Total Assets	-	-	1.62B	1.91B	2.33B	2.72B	3.17B	3.58B	3.87B	4.27B	4.66B	5.32B	3.73B	2.56B	2.84B	-	3.28B	4.63B	4.55B	5.08B
Current Assets	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	1.76B	1.75B	1.67B	2.15B
Cash & Equivalents	514.17M	597.33M	428.52M	341.11M	308.50M	383.99M	481.04M	440.80M	422.18M	487.67M	505.63M	642.32M	796.28M	335.71M	436.69M	-	480.53M	395.08M	325.36M	587.83M
Inventory	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	455.71M	516.24M	477.26M	572.37M
Receivables	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	722.89M	702.17M	733.37M	828.84M
Total Liabilities	-	-	961.89M	1.06B	1.26B	1.50B	1.70B	1.82B	1.98B	2.21B	2.36B	3.09B	2.16B	2.77B	2.61B	-	2.78B	3.48B	2.73B	2.52B
Current Liabilities	-	-	289.51M	394.57M	385.85M	601.86M	504.24M	487.53M	580.49M	564.08M	520.32M	606.16M	448.93M	591.33M	804.98M	-	785.74M	789.58M	789.76M	1.24B
Long Term Debt	-	-	500.00M	500.00M	700.00M	700.00M	1.04B	1.19B	1.24B	1.49B	1.70B	1.90B	1.15B	1.58B	1.21B	-	1.52B	2.31B	1.63B	947.45M
Total Debt	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	1.66B	2.44B	1.70B	1.49B
Total Equity	362.38M	586.08M	661.00M	848.95M	1.07B	1.23B	1.47B	1.76B	1.89B	2.06B	2.30B	2.23B	1.57B	-216.28M	232.14M	-	504.49M	1.15B	1.83B	2.56B
Shares Outstanding	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	162.43M	162.71M	162.96M	163.16M

Cash Flows (Annual)

Figures in USD.

Metric	Dec 2007	Dec 2008	Dec 2009	Dec 2010	Dec 2011	Dec 2012	Dec 2013	Dec 2014	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024	Dec 2025
Operating Cash Flow	370.51M	418.25M	418.26M	457.86M	497.37M	449.28M	484.88M	-	-	642.92M	697.64M	604.45M	643.09M	790.51M	-	611.66M	602.81M	762.12M	652.55M
Investing Cash Flow	-167.91M	18.81M	-419.03M	-411.51M	-355.98M	-296.39M	-464.73M	-	-	-487.92M	-535.75M	1.68B	768.80M	-264.09M	-	-107.97M	-1.44B	-143.09M	-152.25M
Financing Cash Flow	-119.69M	-572.94M	-90.28M	-60.25M	-60.42M	-66.53M	-64.59M	-	-	-115.70M	-63.87M	-2.12B	-1.87B	-440.50M	-	-509.63M	754.95M	-696.67M	-237.21M
Capital Expenditure	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-183.46M	-160.63M	-142.48M	-112.75M
Free Cash Flow	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	428.20M	442.18M	619.64M	539.81M
Net Change in Cash	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-5.94M	-84.50M	-77.64M	263.10M
Share Buybacks	-200.65M	237.50M	211.38M	296.29M	370.83M	295.88M	301.58M	337.44M	334.70M	325.76M	332.54M	1.32B	2.47B	196.41M	648.93M	626.06M	70.28M	13.54M	14.67M

Ratios (Annual)

Figures in %.

Metric	Dec 2007	Dec 2008	Dec 2009	Dec 2010	Dec 2011	Dec 2012	Dec 2013	Dec 2014	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024	Dec 2025
Gross Margin %	57.2%	58.0%	60.3%	60.2%	60.5%	60.0%	58.9%	58.5%	58.7%	-	-	-	-	-	-	58.0%	59.6%	59.4%	59.3%
Operating Margin %	23.7%	24.7%	26.3%	27.4%	28.6%	27.7%	27.2%	26.0%	27.8%	28.8%	28.7%	30.6%	29.4%	27.3%	-	29.7%	27.7%	28.3%	25.4%
Net Margin %	-	-	-	-	-	25.0%	23.6%	21.7%	23.0%	24.1%	0.9%	24.5%	24.6%	22.1%	-	23.8%	21.7%	21.6%	20.3%
ROE %	-	-	-	-	-	31.4%	25.5%	22.8%	22.8%	22.7%	0.9%	37.9%	-273.8%	224.7%	-	140.3%	55.8%	34.9%	25.1%
ROCE %	-	29.2%	26.1%	23.2%	24.9%	19.2%	16.7%	15.7%	15.3%	15.1%	14.0%	22.6%	36.0%	31.7%	-	35.4%	21.3%	22.3%	20.9%

Shareholding Pattern

Insiders

0.10%

Institutions

102.30%

Public Float

102.40%

Top Institutional Holders

#	Holder	% Held	Shares	Value
1	Blackrock Inc.	8.64%	8.48M	$3.52B
2	Vanguard Capital Management LLC	6.53%	6.42M	$2.66B
3	Vanguard Portfolio Management LLC	4.83%	4.74M	$1.97B
4	Massachusetts Financial Services Co.	4.71%	4.63M	$1.92B
5	State Street Corporation	4.46%	4.38M	$1.82B
6	T. Rowe Price Investment Management, Inc.	3.89%	3.82M	$1.58B
7	Invesco Ltd.	3.56%	3.49M	$1.45B
8	Alliancebernstein L.P.	2.74%	2.69M	$1.12B
9	Geode Capital Management, LLC	2.68%	2.64M	$1.09B
10	Fundsmith LLP	2.31%	2.27M	$942.85M

Analyst View

Loading analyst coverage…

Latest News

Recent headlines for WAT

Yahoo Finance Fri, 04 Sep 2026

Waters (WAT) Stock Could Be A Bargain On Cash Flow Yet Fully Priced On Sales

Waters stock has put in a strong multi year gain, yet the valuation signals are split, with an intrinsic value estimate based on a Discounted Cash Flow (DCF) model pointing to upside while the earnings multiple checks lean expensive. Over t…

Yahoo Finance Fri, 04 Sep 2026

Waters (WAT) Raised Guidance, Is The Stock Still Cheap?

Waters (WAT) stock is back in focus after the company reported Q2 2026 adjusted earnings of $3.05 per share and raised its full year guidance for organic revenue growth and adjusted earnings. At a share price of $413.56, Waters has posted a…

Yahoo Finance hu, 03 Sep 2026

Why Is Waters (WAT) Up 3.1% Since Last Earnings Report?

Waters (WAT) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Yahoo Finance Fri, 28 Aug 2026

Is Wall Street Bullish or Bearish on Waters Corporation Stock?

Although Waters Corporation has exceeded the broader market over the past year, Wall Street analysts maintain a cautiously optimistic outlook on the stock’s prospects.

Yahoo Finance Wed, 26 Aug 2026

Research Tools & Consumables Stocks Q2 Highlights: Waters Corporation (NYSE:WAT)

The end of an earnings season can be a great time to discover new stocks and assess how companies are handling the current business environment. Let’s take a look at how Waters Corporation (NYSE:WAT) and the rest of the research tools & con…

Yahoo Finance Wed, 26 Aug 2026

Waters Corporation to Present at the Wells Fargo Healthcare Conference

Waters Corporation (NYSE: WAT) announced that Udit Batra, Ph.D., Waters President and Chief Executive Officer, will participate in a fireside chat at the Wells Fargo 21st Annual Healthcare Conference on Wednesday, September 9th, 2026, at 10…

WAT — Frequently Asked Questions

What is the current share price of Waters Corporation (WAT)?

As of 2026-09-07 16:24 PDT, Waters Corporation (WAT) trades at $409.38 on NYSE. Its 52-week range is $283.32 to $421.26.

What is the market capitalisation of WAT?

Waters Corporation (WAT) has a market capitalisation of $40.20B on NYSE.

What is the P/E ratio of WAT?

WAT trades at a trailing price-to-earnings (P/E) ratio of 101.58. The industry average P/E is 25.17. Its price-to-book (P/B) ratio is 2.61.

What is the return on equity (ROE) of WAT?

WAT has a return on equity (ROE) of 1.92%. Its return on capital employed (ROCE) is 20.92%.

Is WAT a good stock to buy?

This page provides a data-driven analysis of Waters Corporation (WAT), including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.

Explore More

📊 Healthcare Sector 🔍 All Stock Screens 📈 Technical Screens 💰 Fundamental Screens 🔄 Swing Trading Setups 📐 Chart Patterns 📅 Earnings Calendar 📋 All USA Stocks

Waters Corporation WAT SPXR3KPHARMA

Company Overview

Why Investors Should Care

Recent Developments

Growth & Price Performance

Compounded Sales Growth

Compounded Profit Growth

Stock Price Performance

Price Chart

Technical Trend

Fundamental Growth Charts

PROS

CONS

Valuation

Growth (CAGR)

Profitability & Returns

Balance Sheet & Liquidity

Ownership

Financial Snapshot

Peer comparison

Quarterly Results

Profit & Loss (Annual)

Balance Sheet (Annual)

Cash Flows (Annual)

Ratios (Annual)

Shareholding Pattern

Top Institutional Holders

Analyst View

Latest News

Waters (WAT) Stock Could Be A Bargain On Cash Flow Yet Fully Priced On Sales

Waters (WAT) Raised Guidance, Is The Stock Still Cheap?

Why Is Waters (WAT) Up 3.1% Since Last Earnings Report?

Is Wall Street Bullish or Bearish on Waters Corporation Stock?

Research Tools & Consumables Stocks Q2 Highlights: Waters Corporation (NYSE:WAT)

Waters Corporation to Present at the Wells Fargo Healthcare Conference

WAT — Frequently Asked Questions

What is the current share price of Waters Corporation (WAT)?

What is the market capitalisation of WAT?

What is the P/E ratio of WAT?

What is the return on equity (ROE) of WAT?

Is WAT a good stock to buy?

Explore More